GSE179235 MEK NRAS inhibition 0 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE179235_MEK_NRAS inhibition_0_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE179235_MEK_NRAS inhibition_0_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE179235_MEK_NRAS inhibition_0_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE179235_MEK_NRAS inhibition_0_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

synergin gamma

Gene

differentiation antagonizing non-protein coding RNA

Gene

long intergenic non-protein coding RNA 511

Gene

TP53 target 1

Gene

DPPA2 upstream binding RNA

Gene

p53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript

Gene

MIR4458 host gene

Gene

FEZF1 antisense RNA 1

Gene

C2orf74 divergent transcript

Gene

SOX21 antisense RNA 1


  • Gene

    differentiation antagonizing non-protein coding RNA


  • Gene

    long intergenic non-protein coding RNA 511



  • Gene

    DPPA2 upstream binding RNA


  • Gene

    p53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript



  • Gene

    FEZF1 antisense RNA 1


  • Gene

    C2orf74 divergent transcript


  • Gene

    SOX21 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.